Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well temozolomide with or without veliparib works
in treating patients with small cell lung cancer that has returned or does not respond to
treatment. Temozolomide works by damaging molecules inside the cancer cells, such as
deoxyribonucleic acid (DNA), that are needed for cancer survival and growth. Veliparib may
stop the growth of tumor cells by blocking proteins that are needed for repairing the damaged
DNA and it may also help temozolomide to kill more cancer cells. It is not yet know whether
temozolomide is more effective with or without veliparib in treating patients with relapsed
or refractory small cell lung cancer.